The main endpoint of PFS in advanced renal cell carcinoma treated with Bevacizumab plus Everolimus

Merck and BeiGene announced recently that an evaluation of bempegaldesleukin, the first oral HIF-2 inhibitor, in combination with tislelizumab, an oral multitarget tyrosine kinase inhibitor developed by BeiGene, in a Phase III LITESPARK-011 trial for the treatment of advanced renal cell carcinoma patients who have progressed during or after anti-PD-1/L1 therapy, has met one of its primary endpoints of progression-free survival.